全文获取类型
收费全文 | 3048篇 |
免费 | 189篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 76篇 |
妇产科学 | 78篇 |
基础医学 | 402篇 |
口腔科学 | 9篇 |
临床医学 | 295篇 |
内科学 | 674篇 |
皮肤病学 | 60篇 |
神经病学 | 369篇 |
特种医学 | 54篇 |
外科学 | 243篇 |
综合类 | 12篇 |
一般理论 | 8篇 |
预防医学 | 359篇 |
眼科学 | 27篇 |
药学 | 221篇 |
中国医学 | 8篇 |
肿瘤学 | 335篇 |
出版年
2024年 | 3篇 |
2023年 | 43篇 |
2022年 | 62篇 |
2021年 | 136篇 |
2020年 | 75篇 |
2019年 | 128篇 |
2018年 | 140篇 |
2017年 | 71篇 |
2016年 | 94篇 |
2015年 | 114篇 |
2014年 | 145篇 |
2013年 | 187篇 |
2012年 | 312篇 |
2011年 | 314篇 |
2010年 | 152篇 |
2009年 | 128篇 |
2008年 | 174篇 |
2007年 | 186篇 |
2006年 | 161篇 |
2005年 | 127篇 |
2004年 | 125篇 |
2003年 | 89篇 |
2002年 | 94篇 |
2001年 | 21篇 |
2000年 | 17篇 |
1999年 | 21篇 |
1998年 | 13篇 |
1997年 | 5篇 |
1996年 | 9篇 |
1995年 | 7篇 |
1994年 | 8篇 |
1993年 | 4篇 |
1992年 | 9篇 |
1991年 | 13篇 |
1990年 | 10篇 |
1989年 | 11篇 |
1988年 | 4篇 |
1987年 | 6篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1981年 | 4篇 |
1980年 | 2篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 4篇 |
1967年 | 1篇 |
1966年 | 1篇 |
1948年 | 4篇 |
1943年 | 1篇 |
1924年 | 1篇 |
排序方式: 共有3247条查询结果,搜索用时 0 毫秒
31.
Bravo MJ Vallejo F Barrio G Brugal MT Molist G Pulido J Sordo L de la Fuente L;the ITINERE Project Group 《The International journal on drug policy》2012,23(5):415-419
BACKGROUND: Heroin users who do not inject constitute a large pool of drug users with a potentially important impact on public health. We aimed to estimate the incidence of hepatitis C virus (HCV) among heroin users who had never injected (NIDUS) at baseline, and the effect of starting injecting during follow-up, other percutaneous exposures, sharing snorting paraphernalia, cocaine/crack use, and risky sexual behaviour on HCV-seroconversion. METHODS: Prospective cohort of 305 HCV-negative NIDUs at baseline, aged 18-30 and street-recruited in three Spanish cities in 2001-2003. Computer-assisted personal interviews were conducted and dried blood-spot samples were collected. Bivariate and multivariable Poisson models were used. RESULTS: Among the 305 never-injectors who were HCV-negative at baseline, 197 (64.6%) were followed-up and 21 seroconverted [HCV-incidence rate=5.8/100 person-years at risk (pyar) (95% CI: 3.6-8.9)]. HCV incidence in new-injectors was 28.4/100pyar [(95% CI, 14.7-49.7) vs. 2.8/100pyar (95% CI, 1.3-5.4)] among NIDUs. Of the risk exposures considered, starting injecting was the only predictor of HCV-seroconversion [adjusted relative risk=10.1, 95% CI: 3.8-26.7]. CONCLUSION: The HCV-seroconversion rate was 10 times higher among new-injectors than never-injectors. No predictors other than starting injecting were found for HCV-seroconversion. Harm reduction interventions to prevent HCV infection should include prevention of drug injection. 相似文献
32.
33.
34.
Arif Zafar Gemma Ingham Jainudeen K.A. Jameel 《International journal of surgery case reports》2013,4(5):528-530
INTRODUCTIONBouveret's syndrome is a rare variant of gallstone ileus and describes gastric outlet obstruction secondary to an impacted stone in the duodenum. Its presentation is vague and clinical diagnosis is often difficult resulting in a delay in diagnosis.PRESENTATION OF CASEWe report a patient who presented initially with non-specific symptoms and subsequently with features in keeping with acute pancreatitis, but eventually was found to have Bouveret's syndrome.DISCUSSIONDifferent treatment strategies are discussed. Although endoscopic treatment combined with many newer modalities like lithotripsy have been tried, surgery remains the definitive management in the vast majority of cases.CONCLUSIONBouveret's syndrome is a rare condition, can also present as pancreatitis and often difficult to diagnose initially, but with appropriate treatment has a good outcome. 相似文献
35.
36.
José L. Pérez-Castrillón María T. Zarrabeitia Laura Abad Gemma Vega Marta Ruiz-Mambrilla Manuel Gonzalez-Sagredo Antonio Dueñas-Laita José A. Riancho 《Rheumatology international》2014,34(8):1073-1077
Although their primary therapeutic indications are different, aminobisphosphonates and statins target enzymes in the mevalonate pathway, which is critical for bone homeostasis. Previous studies have shown that some polymorphisms of the gene encoding farnesyl diphosphate synthase (FDPS), the main target of aminobisphosphonates, modulate the response to these drugs. In this study, we explored whether those single nucleotide polymorphisms (SNPs) also influence the changes in bone mineral density (BMD) following therapy with statins. Sixty-six patients with coronary heart disease were studied at baseline and after 1-year therapy with atorvastatin. BMD was measured by DXA. Three SNPs of the FDPS gene (rs2297480, rs11264359 and rs17367421) were analyzed by using Taqman assays. The results showed that there was no association between the SNPs and basal BMD. However, rs2297480 and rs11264359 alleles, which are in linkage disequilibrium, were associated with changes in hip BMD following atorvastatin therapy. Thus, patients with AA genotype at the rs2297480 locus had a 0.8 ± 0.8 % increase in BMD at the femoral neck, whereas in patients with AC/CC genotypes, BMD showed a 2.3 ± 0.8 % decrease (p = 0.02). Similar results were obtained regarding changes of BMD at the femoral trochanter and when alleles at the rs11264359 locus were analyzed. However, there was no association between BMD and rs17367421 alleles. In conclusion, these results suggest that polymorphisms of the FDPS gene may influence the bone response to various drugs targeting the mevalonate pathway, including not only aminobisphosphonates but also statins. 相似文献
37.
38.
39.
40.